NGENLA

This brand name is authorized in Canada, Croatia, Estonia, Italy, Japan, Poland, Romania, Turkey.

Active ingredients

The drug NGENLA contains one active pharmaceutical ingredient (API):

1	Somatrogon UNII 6D848RA61B - SOMATROGON
	Somatrogon is a glycoprotein comprised of the amino acid sequence of hGH with one copy of the of C-terminal peptide (CTP) from the beta chain of human chorionic gonadotropin (hCG) at the N-terminus and two copies of CTP (in tandem) at the C-terminus. The glycosylation and CTP domains account for the half-life of somatrogon, which allows for weekly dosing. Somatrogon binds to the GH receptor and initiates a signal transduction cascade culminating in changes in growth and metabolism.
	Read more about Somatrogon

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NGENLA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H01AC08		H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01A Anterior pituitary lobe hormones and analogues → H01AC Somatropin and somatropin agonists
Discover more medicines within H01AC08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02521679, 02521687
EE	Ravimiamet	1875900, 1875911
IT	Agenzia del Farmaco	049913015, 049913027
JP	医薬品医療機器総合機構	2412404G1024, 2412404G2020
PL	Rejestru Produktów Leczniczych	100465918, 100465925
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68503001, W68504001
TR	İlaç ve Tıbbi Cihaz Kurumu	8681308951007, 8681308951106